Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 58, Issue 5, 2009, Pages 708-713

  Saiki, Atsuhito ^a   Ohira, Masahiro ^a   Endo, Kei ^a   Koide, Nobukiyo ^a   Oyama, Tomokazu ^a   Murano, Takeyoshi ^a   Watanabe, Hitoshi ^a   Miyashita, Yoh ^a   Shirai, Kohji ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN II; HEPARIN; LEPTIN; LIPOPROTEIN LIPASE;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; CALORIC INTAKE; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; WEIGHT REDUCTION; WILD TYPE;

ADIPONECTIN; ADIPOSE TISSUE; ANGIOTENSIN II; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; OBESITY; TOMOGRAPHY, X-RAY COMPUTED; WEIGHT LOSS;

EID: 64349083373     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.01.013     Document Type: Article

References (40)

1. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83 (1999) 25-29
2. Nakamura T., Tokunaga K., Shimomura I., et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atheroscrerosis 107 (1994) 239-246
3. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
4. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
5. Ryo M., Nakamura T., Kihara S., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68 (2004) 975-981
6. Shimomura I., Hammer R.E., Ikemoto S., et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401 (1999) 73-76
7. Julius S., Kjeldsen S.E., Weber M., et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
8. Hanefeld H., and Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 29 (2001) 270-279
9. Cheung R., Lewanczuk R.Z., Rodger N.W., et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract 53 (1999) 584-592
10. Miyashita Y., Ito Y., Hasiguchi S., et al. Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus. J Atheroscler Thromb 81 (2001) 25-29
11. Saiki A., Ohira M., Endo K., et al. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract 74 (2006) 242-248
12. Janke J., Engeli S., Gorzelniak K., et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51 (2002) 1699-1707
13. Saiki A., Koide N., Watanabe F., et al. Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system. Metabolism 57 (2008) 1093-1100
14. Karlsson C., Lindell K., Ottosson M., et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 83 (1998) 3925-3929
15. Umemura S., Nyui N., Tamura K., et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 10 (1997) 629-633
16. Goodfriend T.L., Kelley D.E., Goodpaster B.H., et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 7 (1999) 355-362
17. Licata G., Scaglione R., Ganguzza A., et al. Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 7 (1994) 314-320
18. Engeli S., Böhnke J., Gorzelniak K., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45 (2005) 356-362
19. Krug A.W., and Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?. Hypertension 51 (2008) 1252-1258
20. Kanazawa M., Yoshiike N., Osaka T., et al. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet 94 (2005) 1-12
21. Kobayashi H., Shimamoto K., and Moriguchi O. Radioimmunoassay of human plasma angiotensin II. Horumon To Rinsho 27 (1979) 665-669
22. Kobayashi J., Hashimoto H., Fukamachi I., et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chem Acta 216 (1993) 113-123
23. Ma Z., Gingerich R.L., Santiago J.V., et al. Radioimmunoassay of leptin in human plasma. Clin Chem 42 (1996) 942-946
24. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comun 257 (1999) 79-83
25. Tornvall P., Olivecrona G., Karpe F., et al. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 15 (1995) 1086-1093
26. Watanabe H., Miyashita Y., Murano T., et al. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 145 (1999) 45-50
27. Shirai K., Itoh Y., Sasaki H., et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46 (1999) 35-41
28. Kobayashi J., Saito K., Fukamachi I., et al. Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm Metab Res 33 (2001) 412-416
29. Saiki A., Oyama T., Endo K., et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 76 (2007) 93-101
30. Hanyu O., Miida T., Obayashi K., et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174 (2004) 385-390
31. Hanyu O., Miida T., Kosuge K., et al. Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents. Clin Chim Acta 384 (2007) 118-123
32. Furuhashi M., Ura N., Higashiura K., et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
33. Kurukulasuriya L.R., Stas S., Lastra G., et al. Hypertension in obesity. Endocrinol Metab Clin North Am 37 (2008) 647-662
34. Biollaz J., Burnier M., Turini G.A., et al. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 29 (1981) 665-670
35. MacGregor G.A., Markandu N.D., Smith S.J., et al. Angiotensin converting enzyme inhibition reveals an important role for the renin system in the control of normal and high blood pressure in man. Clin Exp Hypertens A 5 (1983) 1367-1380
36. Jackson B., McGrath B.P., and Johnston C.I. Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension. Clin Exp Pharmacol Physiol Suppl 7 (1982) 99-104
37. Shoback D.M., Williams G.H., Hollenberg N.K., et al. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man. J Clin Endocrinol Metab 57 (1983) 764-770
38. Navar L.G., and Nishiyama A. Why are angiotensin concentrations so high in the kidney?. Curr Opin Nephrol Hypertens 13 (2004) 107-115
39. Franco M., Martínez F., Quiroz Y., et al. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 293 (2007) 251-256
40. Chaston T.B., Dixon J.B., and O'Brien P.E. Changes in fat-free mass during significant weight loss: a systematic review. Int J Obes 31 (2007) 743-750